History and development of Sinclair Pharma

Early history

Headquartered in Godalming, Surrey, Sinclair Pharmaceuticals Limited was founded in 1971 by Andrew Sinclair to focus on the sale and marketing of generic and branded pharmaceutical products in the UK.

The company operated in this way until August 2000 when Sinclair Pharmaceuticals Limited was acquired by a management team led by Dr. Michael Flynn and Jerry Randall.

Sinclair development

From August 2000, Sinclair acquired companies and products, and conducted some development work to produce new products or line extensions. The company expanded its portfolio and in September 2003, most of the original UK Sinclair products (including the aspirin brand Caprin) were divested in order to focus on the core new products.

As the company has grown, and since flotation on AIM in December 2003, the corporate strategy has evolved further.  Sinclair has spent recent years developing its direct on-market presence in the key EU territories, and now has sales and marketing operations in the UK, France, Italy, Spain and Portugal.  For further information about the corporate strategy please click here.

Key Events in Sinclair history

Sinclair Pharma has achieved and exceeded numerous goals in recent years. Many products have been acquired and registered. Agreements have been signed and these have proceeded to product launches in a wide range of territories.

Acquisitions

To date, Sinclair Pharma has acquired one company in the UK (Ashbourne Pharmaceuticals Ltd), two companies in Sweden (Salix Pharma AB, Biosurface AB), two in Italy (Propharma Srl, Euroderm RDC Srl) and one with operations in France, Spain and Portugal.  With these companies, Sinclair has expanded its sales and marketing reach, and has also added to its portfolio of pharmaceutical products and intellectual property (IP) rights in the oral health, oncology support or dermatology fields.

Regulatory Approvals

Since the acquisition of the initial three companies, Sinclair Pharma has secured registration and licensing agreements for a number of these three companies' products. It intends to do the same with select products from the Euroderm portfolio.

Agreements with marketing partners

Sinclair Pharma now has a global network of marketing partners, including 96 companies and 82 countries. From an early stage, Sinclair works closely with marketing partners to ensure that they are well prepared for the launch of the product.

Click here for a list of our partner agreements.

Clinical trial results/publications

Where appropriate, Sinclair conducts clinical trials to support the sales and marketing of our products. For example a study was recently completed that demonstrated the efficacy and safety of Atopiclair in 216 patients with atopic dermatitis (link to Atopiclair website).

press releases concerning clinical trials

Flotation

Sinclair Pharma was re-registered as a public limited company on 28 November 2003.

In December 2003, Sinclair was listed on the London Stock Exchange's Alternative Investment Market ("AIM) - SPHL - raising a total of £21.8 million, £8.9million of new capital (net of expenses). The company name changed accordingly to Sinclair Pharma plc.   

In April 2007, Sinclair migrated from AIM to the Official List of the London Stock Exchange and conducted a secondary listing on Euronext Paris.

Further details can be found at our Investor Relations site.

For press releases concerning Sinclair events, please click here.

	Email Alert: If you would like to receive company or product news, please enter your email address here